In onal Application No PC1/IB2004/003077

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K9/107 A61K31/337 A61K38/13 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system tollowed by classification symbols) IPC 7 A61K Documentation searched other than minimum documentation to the extent that such documents are included in the tields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BIOSIS, MEDLINE C. DOCUMENTS CONSIDERED TO BE RELEVANT Category * Citation of document, with indication, where appropriate, of the relevant passages Relevant to claim No. P,X EP 1 340 497 A (NOVAGALI SAS ;YISSUM RES 1-21 DEV CO (IL)) 3 September 2003 (2003-09-03) paragraph '0025! paragraph '0048! claims examples WO 02/43765 A (TRANSFORM PHARMACEUTICALS 1-21 A INC : CHEN HONGMING (US)) 6 June 2002 (2002-06-06) page 4, line 31 - page 5, line 1 page 14, line 4 - line 21 See Formulations G.H.I.J.K -/--Patent family members are listed in annex. X Further documents are listed in the continuation of box C. 9 Special categories of cited documents : *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the *A* document defining the general state of the art which is not considered to be of particular relevance invention "E" earlier document but published on or after the international "X" document of particular relevance; the claimed Invention cannot be considered novel or cannot be considered to filing date involve an inventive step when the document is taken alone document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such docucitation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled in the art. other means *P* document published prior to the international tiling date but later than the priority date claimed "&" document member of the same patent family Date of the actual completion of the international search Date of mailing of the international search report 04/11/2004 26 October 2004 Name and mailing address of the ISA Authorized officer European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Giménez Miralles, J Fax: (+31-70) 340-3016

1 c 1/ IB2004/003077

egory ° Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Agory Chancel of Coolingin, with indication, where appropriate, or the relevant passages	Helevant to claim No.
US 6 509 370 B1 (GORE ASHOK Y ET AL) 21 January 2003 (2003-01-21) column 3, line 8 - column 4, line 8 column 6, line 42 - line 48 examples	1-21
US 6 458 373 B1 (CONSTANTINIDES PANAYIOTI P ET AL) 1 October 2002 (2002-10-01) column 3, line 45 - column 4, line 18 examples	S 1–21
WO 99/45918 A (NAPRO BIOTHERAPEUTICS INC) 16 September 1999 (1999-09-16) page 3, line 3 - line 32 examples 8,10,11	1-21
US 2002/156124 A1 (MOROZOWICH WALTER ET AL) 24 October 2002 (2002-10-24) paragraph '0025! – paragraph '0030! paragraph '0033! – paragraph '0041! paragraph '0072! – paragraph '0079!	1-21
WO 95/11039 A (HEXAL PHARMA GMBH ;KLOKKER: KARIN (DE); FISCHER WILFRIED (DE)) 27 April 1995 (1995-04-27) example 3	S 1-21
WO 00/78247 A (BAKER NORTON PHARMA) 28 December 2000 (2000-12-28) page 8, line 12 - page 9, line 6 page 10, line 18 - page 11, line 21 example 8	1-21

mational application No. PCT/IB2004/003077

INTERNATIONAL SEARCH REPORT

Box II	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This Inte	rnational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos: 21 because they relate to subject matter not required to be searched by this Authority, namely:
	Although claim 21 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. X	Claims Nos: 1-21 in part because they relate to parts of the international Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:
	see FURTHER INFORMATION sheet PCT/ISA/210
з. 🔲	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Fule 6.4(a).
Box III	Observations where unity of Invention is lacking (Continuation of item 3 of first sheet)
This Inte	ernational Searching Authority found multiple inventions in this International application, as follows:
1. 🔲	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
з. 🗌	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remar	k on Protest The additional search fees were accompanied by the applicant's protest.
	No protest accompanied the payment of a difficient search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box II.1

Although claim 21 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleded effects of the compound/composition.

Continuation of Box II.1

Claims Nos.: 21

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

Continuation of Box II.2

Claims Nos.: 1-21 in part

Present claims 1-21 relate to an extremely large number of possible pharmaceutical compositions, namely all those comprising active agent(s) "which have low solubility in water or are water-insoluble" (claim 1).

Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compositions claimed, namely those wherein the active agent is a taxoid (particularly paclitaxel) within the meaning of claims 6 and 7. Compositions comprising other active agents, even if speculatively mentioned in a long list (cf. claim 4), cannot be considered to be sufficiently disclosed in the description, because it is not made credible or shown that the relevant technical problem is effectively solved in the same way for all of the active agents listed in claim 4.

In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compositions as claimed in claim 1 in combination with claims 6 and 7.

The applicant's attention is drawn to the fact that claims relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when Rule 66.1(e) PCT). The applicant is advised that the EPO normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any

FURTHER INFORMATION CONTINUED FROM	PCT/ISA/	210
------------------------------------	----------	-----

Chapter II procedure. If the application proceeds into the regional phase before the EPO, the applicant is reminded that a search may be carried out during examination before the EPO (see EPO Guideline C-VI, 8.5), should the problems which led to the Article 17(2) declaration be overcome.

PUI/IB2004/003077

			62004/00307/		
Patent document cited in search report		Publication date		Patent family member(s)	Publication date
EP 1340497	A	03-09-2003	EP WO	1340497 A1 03074027 A2	03-09-2003 12-09-2003
WO 0243765	A	06-06-2002	AU EP	3928202 A 1337273 A2	11-06-2002 27-08-2003
	B1	21 01 2002	 US	0243765 A2 	06-06-2002 01-08-2002
US 6509370	В1	21-01-2003	US US	6319943 B1 6136846 A	20-11-2001 24-10-2000
			US	2003191179 A1	09-10-2003
			AU CA	7490200 A 2388613 A1	08-05-2001 03-05-2001
			CN	1382038 T	27-11-2002
			EP JP	1225872 A1 2003512416 T	31-07-2002 02-04-2003
			wo	0130319 A1	03-05-2001
US 6458373	B1	01-10-2002	CA EP	2276730 A1 0981328 A1	16-07-1998 01-03-2000
			IN	183539 A1	05-02-2000
			JP TW	2001508445 T 579297 B	26-06-2001 11-03-2004
			WO	9830205 A1	16-07-1998
			US US	2003027858 A1 2003104015 A1	06-02-2003 05-06-2003
			US	2003104015 A1 2003109575 A1	12-06-2003
			US US	2003105156 A1 2003087953 A1	05-06-2003 08-05-2003
			US	2003087953 AI 2003087954 AI	08-05-2003
			US	2003147959 A1	07-08-2003 11-09-2003
			US US	2003170279 A1 6660286 B1	09-12-2003
			US	6667048 B1	23-12-2003
			US Au	2004202712 A1 5731498 A	14-10-2004 03-08-1998
			ZA	9800098 A	08-07-1998
WO 9945918	Α	16-09-1999	AU AU	762926 B2 2902299 A	10-07-2003 27-09-1999
			BR	9904856 A	18-07-2000
			CA CN	2288240 A1 1255852 T	16-09-1999 07-06-2000
			EP	0977562 A1	09-02-2000
			JP WO	2001524988 T 9945918 A1	04-12-2001 16-09-1999
			US	2001029264 A1	11-10-2001
			ZA	9901885 A	10-09-1999
US 2002156124	A1	24-10-2002	BR CA	0206580 A 2434338 A1	16-12-2003 25-07-2002
			CA	2434641 A1	22-08-2002
			CZ EP	20031844 A3 1365812 A2	17-12-2003 03-12-2003
			EP	1365759 A2	03-12-2003
			JP JP	2004520359 T 2004520398 T	08-07-2004 08-07-2004
			NO	20033244 A	17-09-2003
	_				

	atent document d in search report		Publication date		Patent family member(s)		Publication date
US	2002156124	A1		WO WO US	02064132 02056878 2003045563	8 A2	22-08-2002 25-07-2002 06-03-2003
WO	9511039	A	27-04-1995	DE DE WO EP ES JP US	10199039 59409377 9511039 0724452 2148345 9504012	D1 D A1 P A1 D T3 D T3	22-11-2001 29-06-2000 27-04-1995 07-08-1996 16-10-2000 22-04-1997 08-02-2000
WO	0078247	А	28-12-2000	WO AU BR CA CZ EP HU JP NO NZ SK	007824\\ 774066\\ 469559\\ 9917403\\ 2371924\\ 2001458\\ 1221906\\ 0300836\\ 200350234\\ 20016196\\ 51627\\ 1878200) B2) A 3 A 1 A1) A3 3 A1 5 A2) T 3 A	28-12-2000 17-06-2004 09-01-2001 09-07-2002 28-12-2000 17-07-2002 28-08-2003 21-01-2003 05-02-2002 25-06-2004 10-09-2002